High-dose Intravenous Immunoglobulin Delays Clearance of von Willebrand Factor in Acquired von Willebrand Disease

• References

• 1 van Genderen PJ J, Michiels JJ. Clinical manifestations and pathophysiology of acquired von Willebrand’s disease in association with benign monoclonal gammapathies, multiple myeloma and lymphoproliférative disorders. In: Monoclonal gammapathies III - clinical significance and basic mechanisms. Radi J, van Camp B. eds Leiden: EURAGE; 1991. pp 221-225
• 2 Mannucci PM, Lombardi R, Bader R, Horellou MH, Finazzi G, Besana C, Conard J, Samama M. Studies on the pathophysiology of acquired von Willebrand’s disease in seven patients with lymphoproliferative disorders or benign monoclonal gammapathies. Blood 1984; 64: 614-621
• 3 van Genderen PJ J, Michiels JJ, Bakker JJ, van ’t Veer MB. Effectiveness of high-dose gammaglobulin in acquired von Willebrand’s disease. Vox Sang 1994; 67: 14-17
• 4 Arkel Y, Lynch J, Kamiyana M. Treatment of acquired von Willebrand syndrome with intravenous immunoglobulin. Thromb Haemost 1994; 72: 643-644
• 5 Macik BG, Gabriel DA, White GC, High K, Roberts H. The use of highdose intravenous gammaglobulin in acquired von Willebrand disease. Arch Pathol Lab Med 1988; 112: 143-146
• 6 van Genderen PJ J, Papatsonis DN, Michiels JJ, Wielenga JJ, Stibbe J, Huikeshoven FJ M. High-dose intravenous gammaglobulin therapy for acquired von Willebrand disease. Postgrad Med J 1994; 70: 916-920
• 7 van Genderen PJ J, Vink T, Michiels JJ, van ’t Veer MB, Sixma JJ, van Vliet HH D M. Acquired von Willebrand disease caused by an autoantibody selectively inhibiting the binding of von Willebrand factor to collagen. Blood 1994; 84: 3378-3384